Biotech Financial Reports

Browse past and current articles from this publication.

ROCHESTER MEDICAL REPORTS 3RD QTR NET LOSS OF $77.000.(Financial report)
Rochester Medical Corporation (NASDAQ:ROCM), Stewartville, Minn., has announced operating results for its third quarter ended June 30, 2009. The company reported sales of $8,908,000 for the curren . . .

UNITED THERAPEUTICS HAS NET LOSS OF $2.3 MIL 2ND QTR 2009.(Financial report)
United Therapeutics Corporation (NASDAQ:UTHR), Silver Spring, Md., has announced its results of operations for the quarter ended June 30, 2009. Total revenues for the second quarter of 2009 were $ . . .

ANADYS REPORTS NET LOSS OF $6.5 MILLION 2ND QTR 2009.(Financial report)
Anadys Pharmaceuticals, Inc. (NASDAQ:ANDS), San Diego, Calif., a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, has rep . . .

STUDY SHOWS LILLY'S MAJOR IMPACT ON JOBS IN INDIANA.
According to a new study by the Indiana University Kelley School of Business and its Indiana Business Research Center (IBRC), Eli Lilly and Co. (Lilly) contributes about $8 billion to the state's ec . . .

ACHILLION SIGNS $15 MILLION STANDBY EQUITY DISTRIBUTION.
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), New Haven, Conn., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, has entered int . . .

SENESCO SIGNS PACT FOR UP TO $1.0 MILLION IN FINANCING.
Senesco Technologies, Inc. (NYSE Amex: SNT), New Brunswick, N.J., has announced that the company entered into a definitive purchase agreement with Partlet Holdings Ltd. for the issuance and sale of . . .

BIOHEART GETS $2.8 MILLION IN PROCEEDS FROM PIPE FINANCING.
Bioheart, Inc. (OTC Bulletin Board: BHRT), Sunrise, Fla., has announced that commencing on October 1, 2008, and through July 7, 2009, Bioheart, Inc. (the "company") has received proceeds in the amou . . .

CELTIC PHARMA HOLDINGS INVESTS IN NOVACTA BIOSYSTEM.
Celtic Pharma Holdings Advisors LLP ("CPHA"), the advisor to the second Celtic Pharma fund, Celtic Pharma Holdings II LP ("CP2"), has announced its investment in a majority shareholding in Novacta B . . .

BIO-REFERENCE 2ND QTR HAS INCREASE OF 16% FOR FISCAL 2009.
Laboratories, Inc. (NASDAQ: BRLI), Elmwood Park,N.J., has released its second quarter, fiscal year 2009 earnings for the three months ending April 30. The company recorded current quarter revenues o . . .

ALPHA-1 TO GET $1 MILLION IN MATCHING FUNDS FROM TALECRIS.
The Alpha-1 Foundation will receive up to $1 million in grant matching funds from Talecris Biotherapeutics, Inc. to support research into alpha1-antitrypsin deficiency, a genetic condition in which . . .

ZILA REPORTS FISCAL 2009 3RD QTR NET REVENUES OF $8.5 MIL.(Financial report)
Zila, Inc. (Nasdaq:ZILA), Scottsdale, Ariz., has reported financial results for its fiscal 2009 third quarter ended April 30, 2009. "During the third quarter, revenues remained steady, and our cash . . .

R&D SPENDING BY U.S.BIOPHARMACEUTICALS AT RECORD LEVELS IN 2008.
Despite the nation's economic slowdown, America's pharmaceutical research and biotechnology companies invested a record $65.2 billion last year in the research and development of new life-changing m . . .

PALL REPORTS 2009 SECOND QUARTER AND FIRST HALF RESULTS.(Financial report)(Statistical data)
Overview Sales for the six months were $1.1 billion, a decrease of 5.5% or 1.7% in LC, from a year earlier. Net earnings were $82 million, compared to $84.1 million in the period last year. Diluted . . .

AMAG REPORTS $21.8 MILLION NET LOSS FOR 4TH QTR 2008.(AMAG Pharmaceuticals Inc.)(Financial report)(Statistical data)
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Lexington, Mass., a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron comp . . .

TRANSGENOMIC REPORTS NET LOSS OF $495,000 FOR FISCAL 2008.(Financial report)
Transgenomic, Inc., (OTC Bulletin Board: TBIO), Omaha, Neb., has announced financial results for the fourth quarter and year ended December 31, 2008. The company's financial results are presented in . . .

COVIDIEN FIRST-QTR 2009 NET SALES ROSE 6% TO $2.5 BILLION.
Covidien Ltd. (NYSE: COV; BSX: COV), Hamilton, Bermuda, has reported results for the first quarter of fiscal 2009 (October - December 2008). First-quarter net sales rose 6% to $2.5 billion from $2.3 . . .

GENESIS PHARMACEUTICALS TO BUY HONGRUI PHARMACEUTICALS.
Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH; "Genesis" or the "company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, has a . . .

SEATTLE GENETICS REPORTS ON 2008 AND 2009 OUTLOOK.
"Our 2008 accomplishments were marked by substantial progress across our product pipeline, in particular by successfully demonstrating the therapeutic potential of SGN-35 and the promise of our anti . . .

MONOGRAM REPORTS RECORD 2008 REVENUE AND 2009 GUIDANCE.(Financial report)
Monogram Biosciences, Inc. (Nasdaq:MGRM), South San Francisco, announced that it expects to report revenues of approximately $62 million for the year ended December 31, 2008, an increase of 44% over . . .

GENENTECH REPORTS FULL YEAR/4TH QUARTER 2008 RESULTS.(Financial report)
Genentech, Inc. (NYSE:DNA), South San Francisco, has announced financial results for the full year and fourth quarter of 2008. Key results for the full year 2008 include: U.S. product sales of $9, . . .

ENZO BIOCHEM REPORTS RECORD FISCAL 2009 FIRST QUARTER REVENUE.(Financial report)
Enzo Biochem, Inc. (NYSE:ENZ), a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, has ann . . .

BIODEL INC. REPORTS 4TH QTR FISCAL YEAR 2008 NET LOSS.(Financial report)(Brief article)
Biodel Inc. (Nasdaq: BIOD), Danbury, Conn., has reported financial results for the fourth quarter and fiscal year ended September 30, 2008 and reviewed recent corporate activities and plans. Fourt . . .

VALEANT TO ACQUIRE DOW PHARMACEUTICAL SCIENCES FOR $285 MIL.
Valeant Pharmaceuticals International (NYSE:VRX) has signed a definitive agreement to acquire Dow Pharmaceutical Sciences, Inc., a privately held dermatology company that specializes in the developm . . .

ACHILLION REPORTS 3RD QTR 2008 NET LOSS OF $6.7 MILLION.(Financial report)
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), New Haven, Conn., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, has reported fi . . .

AVIGEN REPORTS A NET LOSS OF $9.4 MIL FOR 3RD QTR 2008.(Financial report)
Avigen, Inc. (Nasdaq:AVGN), Alameda, Calif. a biopharmaceutical company innovating therapeutics for neurological care, has reported financial results for its third quarter ended September 30, 2008. . . .

INSMED REPORTS NET LOSS OF $2.2 MILLION FOR 3RD QTR 2008.(Financial report)
Insmed Inc. (Nasdaq: INSM), Richmond, Va., a developer of follow-on biologics and biopharmaceuticals, has reported results for the third quarter and nine-months ended September 30, 2008. Recent Co . . .

VIRTUALSCOPICS REPORTS INCREASED 3RD QTR 2008 REVENUES.(VirtualScopics)(Financial report)
VirtualScopics, Inc. (NASDAQ:VSCP), Rochester, N.Y., a provider of quantitative imaging for clinical trials, has announced preliminary revenues for the third quarter ended September 30, 2008 were ap . . .

MONSANTO REVISES FULL-YEAR 2OO8 EPS GUIDANCE.(Financial report)
Monsanto Company (NYSE:MON), ST. Louis, has raised its fiscal year 2008 ongoing earnings per share (EPS) guidance to a range of $3.58 to $3.60, and has revised its reported EPS guidance to a range o . . .

DFB SELLS CORIA LABS TO VALEANT PHARMACEUTICALS.
H. Paul Dorman, chairman and CEO of Fort Worth-based DFB Pharmaceuticals, Inc., has announced that DFB has signed a definitive agreement to sell its dermatology division Coria Laboratories, Ltd. to . . .

BIOMS MEDICAL RECEIVES MILESTONE PAYMENT FROM ELI LILLY.
BioMS Medical Corp. (TSX: MS), Edmonton, a leading developer in the treatment of multiple sclerosis (MS), has announced that it has received the US$10 million milestone payment from its partner, Eli . . .

ENCORIUM GETS $6.2 MIL FOR PRIMARILY VACINE TRAILS.
Encorium Group, Inc. (NASDAQ:ENCO), Wayne, Pa., a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials a . . .

AVIGEN REPORTS NET LOSS OF $7.3 MIL FOR 2ND QTR 2008.(Financial report)
Avigen, Inc. (Nasdaq:AVGN), Alameda, Calif., a biopharmaceutical company innovating therapeutics for neurological care, has reported financial results for its second quarter ended June 30, 2008. At . . .

SANGAMO REPORTS NET LOSS OF $7.4 MIL FOR 2ND QTR 2008.(Financial report)
Sangamo BioSciences, Inc. (NASDAQ:SGMO), Richmond, Calif., has reported second quarter 2008 financial results and accomplishments. For the second quarter ended June 30, 2008, Sangamo reported a co . . .

COMPUGEN REPORTS NET LOSS OF $3.0 MIL FOR 2ND QTR 2008.(Financial report)
Compugen Ltd. (NASDAQ: CGEN), Tel Aviv, Israel, has reported its results for the second quarter ending June 30, 2008. Compugen President and CEO Alex Kotzer stated, "During this past quarter, the . . .

CUBIST REPORTS FIRST $100 MILLION REVENUE QUARTER.(Financial report)
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), Lexington, Mass., has reported its first $100 million revenue quarter. For the second quarter ended June 30, 2008, Cubist's net revenues from CUBICIN (da . . .

GILEAD SCIENCES REPORTS 2ND QTR REVENUES OF $1.28 BILLION.(Financial report)
Gilead Sciences, Inc.(Nasdaq: GILD), Foster City, Calif., has announced its results of operations for the quarter ended June 30, 2008. Total revenues for the second quarter of 2008 were $1.28 billio . . .

GENENTECH GETS $625 MILLION 2ND QTR ROYALTY REVENUE.(Financial report)
Genentech, Inc., South San Francisco, Calif., (NYSE: DNA) has announced financial results for the second quarter of 2008. Key results for the second quarter of 2008 include: U.S. product sales of $2 . . .

INIMEX RAISES US $22 MIL AGAINST ANTIBIOTIC RESISTANCE.
Inimex Pharmaceuticals, Inc., Vancouver, BC, has announced the closing of a US $22 Million Series B venture financing. Leading the round was Morningside Venture Investments Ltd., joined by additiona . . .

SEATTLE GENETICS HAS FIRST QTR 2008 NET LOSS OF $17.I MIL.(Financial report)
Seattle Genetics, Inc. (Nasdaq:SGEN) Bothell, Wash., has reported financial results for the first quarter of 2008. "We continue to advance and expand our robust product pipeline, including recent tr . . .

AVIGEN REPORTS FIRST QTR 2008 NET LOSS OF $7.4 MILLION.(Financial report)
Avigen, Inc. (Nasdaq:AVGN), Alameda, Calif., a biopharmaceutical company innovating therapeutics for neurological care, has reported financial results for its first quarter ended March 31, 2008. At . . .

CURIS REPORTS FIRST QTR 2008 NET LOSS OF $3.4 MILLION.(Financial report)
Curis, Inc. (NASDAQ:CRIS), Cambridge, Mass., a drug development company focused on seeking to develop the next generation of targeted medicines for cancer treatment, has reported its financial resul . . .

TRANSAVE, INC. RAISES $35 MILLION VIA PREFERRED STOCK.
Transave, Inc., Monmouth Junction, N.J., a biopharmaceutical company focused on developing innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases has raised an a . . .

NEOPHARM REPORTS 2007 4TH QTR NET LOSS OF $1.1 MILLION.(Financial report)
NeoPharm, Inc. (NASDAQ:NEOL), Waukegan, Ill., has announced its fourth quarter and full year 2007 financial results. For the fourth quarter ended December 31, 2007, NeoPharm reported a net loss of . . .

REGENEREX REPORTS 2007 4TH QTR NET LOSS OF $3.5 MILLION.(Financial report)
RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN), Bethesda, Md., has announced results for the fourth quarter and year ended December 31, 2007. The company reported a net loss of $11.2 million or $0.24 . . .

CANTEL MEDICAL REPORTS 18% INCREASE IN SALES FOR 2ND QTR 2008.(Financial report)
Cantel Medical Corp. (NYSE:CMN), Little Falls, N.J., reported income from continuing operations of $2,157,000, or $0.13 per diluted share (inclusive of approximately $0.02 of stock-based compensatio . . .

PURE BIOSCIENCE REPORTS 2ND FISCAL QTR NET LOSS OF 1,553,700.(Financial report)
PURE Bioscience (OTCBB: PURE), San Diego, Calif., has reported revenues for the second fiscal quarter ended January 31, 2008 of approximately $152,400 compared with revenues of $168,800 in the secon . . .

ACCENTIA REPORTS FISCAL 2007 YEAR-END NET LOSS OF $76.0 MIL.(Financial report)
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), Tampa, Fla., has announced that the company has filed its Annual Report (Form 10-K) with the SEC, reporting the results of its operations for the fis . . .

HAEMACURE REPORTS RECORD REVENUES OF $119,704 IN FISCAL 2007.(Financial report)
Haemacure Corporation (TSX:HAE), a Montreal-based specialty bio-therapeutics company, has announces the results of the fiscal year ended October 31, 2007 and provides an update on activities. Haem . . .

BIOMET 2ND QTR FISCAL 2008 NET SALES INCREASED 11%.
Biomet, Inc., Warsaw, Ind., has announced financial results for its second fiscal quarter ended November 30, 2007. Worldwide reconstructive device sales increased 15% reported (12% constant curren . . .

SAMARITAN ANTICIPATES CONTINUED GROWTH IN 2008.
Samaritan Pharmaceuticals, Inc. (OTCBB:SPHC), a biopharmaceutical company focused on developing innovative therapeutics in the areas of CNS, cancer, cardiovascular, and infectious diseases, announce . . .